secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001213900-25-073089
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio posts $24.5M net loss, CEO replaced; INKmune trial meets endpoints
-----------------------------------------------------------------------------

- Net loss $24.5M in Q2 2025 vs $9.7M in Q2 2024; includes $16.5M impairment of in-process R&D intangibles.
- CEO RJ Tesi retires; David Moss appointed President & CEO; Cory Ellspermann Interim CFO.
- INKmune CaRe PC trial in mCRPC met primary safety and secondary endpoints; trial closed to enrollment.
- XPro MINDFuL trial missed primary cognitive endpoints overall; positive trends in enriched biomarker subset.
- Cash $33.4M as of June 30; completed $19M registered direct offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/0001213900-25-073089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/ea0251921-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer